Project Grant R03HL183276
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $1,254,849 on September 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop engineered small extracellular vesicles for treating diabetic ischemic heart failure. The research addresses the mechanism by which type 2 diabetes confers treatment resistance in ischemic heart failure, focusing on downregulation of CTRP9, a cardioprotective cardiokine that impairs small...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $1,233,682 on May 1, 2026, for research bridging basic and clinical science to prevent cardiovascular disease in diabetes under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses residual cardiovascular disease risk in youth and adults with type 1 and type 2 diabetes despite standard LDL-cholesterol-lowering interventions. The project investigates whether increased hepatic...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $753,662 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardioprotective effects of fibroblast growth factor 16 (FGF16) in diabetic cardiomyopathy. The research examines how a novel recombinant human FGF16 mutant (rhFGF16Δ33) prevents type 2 diabetes-induced cardiac hypertrophy, inflammation, fibrosis, and dysfunction in diabetic mouse models, with particular...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Virginia $782,459 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the impact of obesity on microvascular insulin action and cardiorespiratory fitness in individuals with Type 1 Diabetes. The research will test the hypothesis that endothelial oxidative stress and microvascular insulin resistance lead to reduced skeletal and...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Indiana University Indianapolis a Project Grant of $169,444.00 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 5, 2025, with completion targeted for August 31, 2030. This award supports the co-development and pilot testing of a stress management intervention designed specifically for Black adults with elevated blood pressure and hypertension. The research addresses...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $665,254 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a hybrid type II effectiveness-implementation cluster-randomized trial evaluating ASPIRE, a low-burden implementation toolkit integrating self-measured blood pressure monitoring into primary care workflows. ASPIRE addresses barriers to adoption of self-measured blood pressure monitoring in...
- The National Heart, Lung, and Blood Institute awarded Georgia TECH Research Corp $593,993 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop data-driven restless multi-armed bandit (RMAB) computational models that optimize allocation of public health interventions for diabetes, cardiovascular disease, and maternal health. The project delivers contextual, network-based, and multi-agent RMAB algorithms that integrate observational electronic health...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
The National Heart, Lung, and Blood Institute awarded Florida State University $218,937 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a two-year research project examining high-resistance inspiratory muscle strength training (IMST) as an intervention to reduce systolic blood pressure and improve vascular function among adults with type 1 diabetes. The project runs through July 31, 2028, with work performed in Tallahassee, Florida. Type 1 diabetes carries a nine- to forty-three-year shortened life expectancy and a tenfold higher cardiovascular disease risk compared to the general population. Systolic blood pressure is a leading modifiable risk factor for cardiovascular disease in this population, and even young adults with type 1 diabetes show vascular dysfunction and elevated risk for adverse cardiovascular events and mortality. The research team will investigate IMST as a time-efficient, home-based alternative to traditional aerobic exercise, which presents adherence barriers for people with type 1 diabetes due to low time availability and challenges maintaining euglycemia during physical activity. Published data and preliminary findings demonstrate that IMST reduces systolic blood pressure and improves vascular function in clinical populations and achieves high adherence rates exceeding eighty-five percent because the intervention requires just five minutes daily using a commercially available device. This award is classified as a Project Grant, with total obligated funding of $218,937.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $218.9k | 8/7/26 |